Paper36959802
Rethinking glutamine metabolism and the regulation of glutamine addiction by oncogenes in cancer.
Ni R and 6 others. Front Oncol, 2023. Cited by 49 papers, by iCite.
Cite this record
ConductScience Library. Rethinking glutamine metabolism and the regulation of glutamine addiction by oncogenes in cancer. Papers, record 36959802. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36959802
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Rethinking glutamine metabolism and the regulation of glutamine addiction by oncogenes in cancer.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References227
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32859034 | Amino Acid Transporters as Targets for Cancer Therapy: Why, Where, When, and How. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/32859034 | PubMed |
| 2 | 21993244 | RAS oncogenes: weaving a tumorigenic web. | Nat Rev Cancer | 2011 | https://conductscience.org/library/papers/21993244 | PubMed |
| 3 | 29100325 | Effects of targeting SLC1A5 on inhibiting gastric cancer growth and tumor development in vitro and in vivo. | Oncotarget | 2017 | https://conductscience.org/library/papers/29100325 | PubMed |
| 4 | 25947346 | Glutamate dehydrogenase is a novel prognostic marker and predicts metastases in colorectal cancer patients. | J Transl Med | 2015 | https://conductscience.org/library/papers/25947346 | PubMed |
| 5 | 32483461 | Interplay between MycN and c-Myc regulates radioresistance and cancer stem cell phenotype in neuroblastoma upon glutamine deprivation. | Theranostics | 2020 | https://conductscience.org/library/papers/32483461 | PubMed |
| 6 | 26444490 | Ligand Discovery for the Alanine-Serine-Cysteine Transporter (ASCT2, SLC1A5) from Homology Modeling and Virtual Screening. | PLoS Comput Biol | 2015 | https://conductscience.org/library/papers/26444490 | PubMed |
| 7 | 32907836 | 5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against PIK3CA-Mutant Colorectal Cancers. | Cancer Res | 2020 | https://conductscience.org/library/papers/32907836 | PubMed |
| 8 | 24696726 | Expression of glutaminase is upregulated in colorectal cancer and of clinical significance. | Int J Clin Exp Pathol | 2014 | https://conductscience.org/library/papers/24696726 | PubMed |
| 9 | 33320840 | Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer. | J Clin Invest | 2021 | https://conductscience.org/library/papers/33320840 | PubMed |
| 10 | 35955600 | Development of Sesamol Carbamate-L-Phenylalanine Prodrug Targeting L-Type Amino Acid Transporter1 (LAT1) as a Potential Antiproliferative Agent against Melanoma. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35955600 | PubMed |
| 11 | 10619430 | Molecular analysis of system N suggests novel physiological roles in nitrogen metabolism and synaptic transmission. | Cell | 1999 | https://conductscience.org/library/papers/10619430 | PubMed |
| 12 | 30293904 | Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion. | Eur Urol | 2019 | https://conductscience.org/library/papers/30293904 | PubMed |
| 13 | 24094812 | Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. | Cancer Cell | 2013 | https://conductscience.org/library/papers/24094812 | PubMed |
| 14 | 30258985 | ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancer. | Sci Adv | 2018 | https://conductscience.org/library/papers/30258985 | PubMed |
| 15 | 21813650 | Green tea polyphenols control dysregulated glutamate dehydrogenase in transgenic mice by hijacking the ADP activation site. | J Biol Chem | 2011 | https://conductscience.org/library/papers/21813650 | PubMed |
| 16 | 29156762 | Glutaminase inhibition in multiple myeloma induces apoptosis via MYC degradation. | Oncotarget | 2017 | https://conductscience.org/library/papers/29156762 | PubMed |
| 17 | 34508258 | The MYC oncogene - the grand orchestrator of cancer growth and immune evasion. | Nat Rev Clin Oncol | 2022 | https://conductscience.org/library/papers/34508258 | PubMed |
| 18 | 20513425 | Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. | Mol Cell | 2010 | https://conductscience.org/library/papers/20513425 | PubMed |
| 19 | 34944790 | Transcriptional Regulation of Amino Acid Transport in Glioblastoma Multiforme. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34944790 | PubMed |
| 20 | 30071532 | SLC1A5 Silencing Inhibits Esophageal Cancer Growth via Cell Cycle Arrest and Apoptosis. | Cell Physiol Biochem | 2018 | https://conductscience.org/library/papers/30071532 | PubMed |
Cited by30
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 49 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42457245 | Serum 1H NMR-Based Untargeted Metabolomics for Noninvasive Early Detection of Breast Cancer. | J Proteome Res | 2026 | https://conductscience.org/library/papers/42457245 | PubMed |
| 42123759 | Plant-Derived Modulators of Tumor Metabolism as Novel, Efficacious, and Low-Toxicity Therapeutic Agents for Cancer Treatment. | Molecules | 2026 | https://conductscience.org/library/papers/42123759 | PubMed |
| 42051118 | Glutamine metabolic enzymes: to filament or not to filament? | Biochem Soc Trans | 2026 | https://conductscience.org/library/papers/42051118 | PubMed |
| 41930159 | Advances in Metabolic Reprogramming and Immune Regulatory Mechanisms in Lung Cancer. | Oncol Res | 2026 | https://conductscience.org/library/papers/41930159 | PubMed |
| 41750317 | Advances in Next-Generation Immunotherapies for Ovarian Cancer: Mechanisms of Immune Evasion and Novel Therapeutic Targets. | Biomolecules | 2026 | https://conductscience.org/library/papers/41750317 | PubMed |
| 41744893 | Metabolic Vulnerabilities as a Therapeutic Target in Breast Cancer. | Curr Oncol | 2026 | https://conductscience.org/library/papers/41744893 | PubMed |
| 41715146 | Hydrostatic pressure regulates glutamine metabolism to promote bladder fibroblast activation via the Piezo1/YAP1/GLS1 axis. | J Transl Med | 2026 | https://conductscience.org/library/papers/41715146 | PubMed |
| 41624839 | Immunometabolic editing of the tumor microenvironment: from reprogramming mechanisms to therapeutic vulnerabilities. | Front Immunol | 2025 | https://conductscience.org/library/papers/41624839 | PubMed |
| 41584608 | Pharmacological strategies to overcome immune checkpoint inhibitor resistance in non-small cell lung cancer. | Front Oncol | 2025 | https://conductscience.org/library/papers/41584608 | PubMed |
| 41510103 | Glutamine metabolism drives tumor aggressiveness but not chemoresistance in ovarian carcinoma cell lines. | Transl Cancer Res | 2025 | https://conductscience.org/library/papers/41510103 | PubMed |
| 41324718 | Glutamine reprogramming affects the tumor microenvironment and immune response in hepatocellular carcinoma. | Mol Biol Rep | 2025 | https://conductscience.org/library/papers/41324718 | PubMed |
| 41235226 | Metabolism in the tumor microenvironment: implications for pathogenesis and therapeutics. | Front Immunol | 2025 | https://conductscience.org/library/papers/41235226 | PubMed |
| 41050887 | Novel biomarker identification for oral squamous cell carcinoma development in nonsmoker, nondrinker, and nonchewer patients using third-generation sequencing of oral microbiome. | J Oral Microbiol | 2025 | https://conductscience.org/library/papers/41050887 | PubMed |
| 40941035 | The Underlying Mechanisms and Emerging Strategies to Overcome Resistance in Breast Cancer. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40941035 | PubMed |
| 40917745 | Targeting Wnt-driven metabolic adaptations in cancer: integrating glycolysis, glutaminolysis, IDO1-mediated immune evasion, and therapeutic delivery strategies. | Front Cell Dev Biol | 2025 | https://conductscience.org/library/papers/40917745 | PubMed |
| 40642957 | Metabolic hallmarks of trastuzumab resistance. | Expert Opin Ther Targets | 2025 | https://conductscience.org/library/papers/40642957 | PubMed |
| 40487432 | Lifting the veil on tumor metabolism: A GDH1-focused perspective. | iScience | 2025 | https://conductscience.org/library/papers/40487432 | PubMed |
| 40483365 | Elucidating Ras protein as a dual therapeutic target for inflammation and cancer: a review. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40483365 | PubMed |
| 40260402 | Metabolic readouts of tumor instructed normal tissues (TINT) identify aggressive prostate cancer subgroups for tailored therapy. | Front Mol Biosci | 2025 | https://conductscience.org/library/papers/40260402 | PubMed |
| 40091629 | Application of Metabolic Biomarkers in Breast Cancer: A Literature Review. | Ann Lab Med | 2025 | https://conductscience.org/library/papers/40091629 | PubMed |
Genes59
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36959802
GET https://conductscience.org/api/papers/v1/36959802/references?page=2